STOCK TITAN

Eloxx Pharmaceuticals Inc - ELOX STOCK NEWS

Welcome to our dedicated news page for Eloxx Pharmaceuticals (Ticker: ELOX), a resource for investors and traders seeking the latest updates and insights on Eloxx Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eloxx Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eloxx Pharmaceuticals's position in the market.

Rhea-AI Summary
Almirall and Eloxx Pharmaceuticals sign an exclusive license agreement for ZKN-013, a promising oral therapy for rare dermatological diseases caused by nonsense mutations. Almirall gains global rights to develop and commercialize the drug, with Eloxx receiving substantial upfront payment and milestone royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.29%
Tags
none
-
Rhea-AI Summary
Eloxx Pharmaceuticals, Inc. (OTC: ELOX) reported positive results from its Phase 2 open-label clinical trial of ELX-02 for Alport Syndrome treatment. Kidney morphology improved, and there was a 60% average improvement in podocyte foot process effacement. The company also made significant progress towards a strategic partnership for ZKN-013 and raised additional cash to strengthen its balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.78%
Tags
earnings
-
Rhea-AI Summary
Cognito Therapeutics appoints Greg Weaver as CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
management
Rhea-AI Summary
Cognito Therapeutics appoints Greg Weaver as CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
management
-
Rhea-AI Summary
Cognito Therapeutics appoints Greg Weaver as CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.88%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
clinical trial
Rhea-AI Summary
Eloxx Pharmaceuticals announces definitive agreement for the issuance and sale of common stock and warrants, expected to raise approximately $2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
offering
-
Rhea-AI Summary
Eloxx Pharmaceuticals receives additional confirmation on positive TEM assessment results for ELX-02 in Alport syndrome treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
clinical trial
-
Rhea-AI Summary
Eloxx Pharmaceuticals submits IND application for ELX-02 for Alport syndrome treatment. Positive results from Phase 2 trial show disease regression and protein restoration. Strategic interest in ZKN-013 also reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
none
Rhea-AI Summary
Eloxx Pharmaceuticals announced positive results from its Phase 2 clinical trial of ELX-02 for the treatment of Alport syndrome. All three patients showed improvement in kidney biopsies, demonstrating the disease-modifying effect of ELX-02. Eloxx plans to advance ELX-02 into a pivotal trial for Alport syndrome. In addition, the company received FDA clearance to begin a study of ZKN-013 and raised $3.4 million in net proceeds through an equity offering program. Eloxx also received an extension from Nasdaq to regain compliance with listing requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.63%
Tags
earnings
Eloxx Pharmaceuticals Inc

OTC:ELOX

ELOX Rankings

ELOX Stock Data

3.14M
2.78M
0.41%
18.53%
0.7%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Waltham

About ELOX

eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin